Barclays Cuts UnitedHealth (UNH) Price Target to $440

Barclays reiterates its Overweight rating on UnitedHealth Group with a revised price target of $440, a 9.36% upside from the current price.

By TradeTexts Research Desk · Published Oct 15, 2026, 9:18 PM EDT · Updated Oct 16, 2026, 1:55 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays cut its price target on UnitedHealth Group Incorporated ($UNH) to $440 from $441 on October 14, 2026, and rates the stock "Overweight".

Since the rating, $UNH is up 1.5% to date (from the $395.62 close on Oct 14, 2026).

UNH UnitedHealth Group Incorporated

$401.43 +21.69% year to date

Daily close · Oct 16, 2026

Key Points

On October 14, 2026, Barclays reiterated its Overweight rating on UnitedHealth Group and set a price target of $440, down from $441.
Barclays's $440 price target implies 9.36% upside from UnitedHealth Group Incorporated's ($UNH) current $402.35 share price.
The stock recently traded at $402.35, which is approximately 15.7% below the mean analyst price target of $477.04.
UnitedHealth has a P/E ratio of 26.15 and is expected to report earnings on January 26, 2027.

Get $UNH trade alerts by text

We text you when insiders, Congress or big funds trade $UNH. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated UnitedHealth Group Incorporated alert may contain errors. Disclosures

Barclays reiterated its Overweight rating on UnitedHealth Group Incorporated (NYSE: UNH) on October 14, 2026, lowering its price target to $440 from $441. The stock was recently trading at $402.35, which is below the average analyst target of $477.04.

Barclays' Call on UnitedHealth Group

Barclays maintains an Overweight rating on UnitedHealth Group and has set a new price target of $440. This adjustment comes as the stock trades significantly below the mean target price, suggesting a potential upside.

Other Institutional Activity in UnitedHealth Group

Several other institutions have also been active with their positions in UnitedHealth Group. Blackrock Inc. increased its stake by 3,394,259 shares, bringing its total to 76,863,061 shares valued at approximately $30.9 billion. Vanguard Capital Management LLC added 441,525 shares, ending with 59,311,525 shares worth about $23.8 billion. State Street Corporation grew its holdings by 299,205 shares, totaling 45,633,267 shares valued at around $18.3 billion. Capital World Investors increased its stake by 2,103,297 shares, reaching a total of 29,887,932 shares valued at about $12.0 billion. FMR, LLC also boosted its holdings significantly by 15,974,192 shares, amounting to a total of 27,992,995 shares worth approximately $11.2 billion.

UnitedHealth Group Incorporated Stock Up 1.7%

UnitedHealth shares are currently trading above their 50-day and 200-day moving averages by 3.9% and 12.2%, respectively. However, they are about 12.8% below the 52-week high of $461.62, indicating that the stock has some room for growth. The recent trading price of $402.35 suggests that it may be a good entry point for investors looking for value.

12-month forecast

$UNH price target

UnitedHealth Group Incorporated daily closes and this analyst's $440 target. Not advice.

Recent Earnings

UnitedHealth reported trailing twelve-month revenue of $450.1 billion and an EPS of $15.55. Its net profit margin stands at 3.5%, while the return on equity is 15.8%. The company will announce its next earnings on January 26, 2027.

Insider Buying and Selling at UnitedHealth Group Incorporated

Insider trading activity shows that Patrick Hugh Conway, an officer, sold 1,169 shares on August 21, 2026, at an average price of $390, totaling $455,910. Earlier, he sold 500 shares on August 5, 2026, for $205,000 at an average price of $410. Both transactions were not part of a planned sale.

Analysts Set New Price Targets

On October 14, 2026, Barclays maintained its Overweight rating on UnitedHealth with a price target of $440. That same day, Piper Sandler also maintained its Overweight rating, revising its target to $504 from $502. TD Cowen maintained a Hold rating with a target of $402, down from $430. According to analysts, the consensus recommendation for UnitedHealth is a Buy, with a mean price target of $477.04 based on 25 opinions.

About UnitedHealth Group

UnitedHealth Group Incorporated is a leading healthcare company that operates in the U.S. and internationally. It has four main segments: Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare. The company provides a range of health services, including care delivery and management, making it a significant player in the healthcare sector.

Bottom Line

Investors should watch for UnitedHealth's upcoming earnings report on January 26, 2027, and any further updates on analyst ratings and price targets. Barclays' latest move reflects a cautious but optimistic stance on the stock's potential.